Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nedaplatin + paclitaxel liposome
- Development stage
- Unknown
- Lead developer
- Chinese Academy of Medical Sciences
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy consists of nedaplatin, a second-generation platinum-based chemotherapeutic agent, and a liposomal formulation of paclitaxel, a microtubule-stabilizing taxane. It is being evaluated by the Chinese Academy of Medical Sciences as part of a concurrent chemoradiotherapy (CCRT) regimen following endoscopic resection for patients with high-risk stage I esophageal squamous cell carcinoma (ESCC). Nedaplatin acts by forming DNA adducts that inhibit DNA replication and transcription, while paclitaxel liposome interferes with the breakdown of microtubules during cell division, leading to cell cycle arrest and apoptosis. The liposomal delivery system for paclitaxel is designed to improve solubility and potentially reduce the incidence of hypersensitivity reactions compared to traditional solvent-based formulations.
- Other names
- nedaplatin and paclitaxel liposomepaclitaxel liposome and nedaplatinchemotherapy-Chinese Academy of Medical Sciences-esophageal squamous cell carcinoma
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on nedaplatin + paclitaxel liposome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nedaplatin + paclitaxel liposome.